Search Results

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the publication of two-year follow-up data of CYP-001 in patients with steroid-resistant acute graft versus host disease in the prestigious peer-reviewed journal Nature Medicine.

Cynata Therapeutics Limited (ASX: “CYP” or “Cynata”), a clinical-stage biotechnology company specialising in cell therapeutics, is delighted to announce that the Australian Government National Health and Medical Research Council (NHMRC) has awarded a grant of approximately $1 million under the NHMRC 2021 MRFF Cardiovascular Health Mission

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce the completion of patient enrolment in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers.

Cynata Therapeutics Limited is delighted to announce that the LUMC is funding an important clinical trial to investigate Cynata’s Cymerus™ MSCs as a treatment for renal graft rejection and to potentially reduce the requirement for anti-rejection drugs.

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, confirms that the first patient has been enrolled and treated in its Phase 2 clinical trial of CYP-001 in high-risk acute graft versus host disease.

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, has completed initial analysis of wound surface area in the first 16 patients in its Phase 1 clinical trial of CYP-006TK in diabetic foot ulcers, up to the 10-week follow-up time point.

Cynata Therapeutics Limited, a clinical-stage biotechnology company specialising in cell therapeutics, is pleased to announce that it has received approval by the Central Adelaide Local Health Network Human Research Ethics Committee to commence a clinical trial of Cynata’s Cymerus™ mesenchymal stem cell product in patients with diabetic foot ulcers.

Cynata Therapeutics Limited (ASX: “CYP”, “Cynata”, or the “Company”), a clinical-stage biotechnology company specialising in cell therapeutics, has today announced that the first patient has been enrolled in its MEND (MEseNchymal coviD-19) clinical trial.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system

US FDA has cleared Cynata’s IND application for a Phase 2 clinical trial of CYP-001 in patients with aGvHD – a major milestone and value catalyst for the Company.